Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 108
Filter
1.
Haemophilia ; 24(1): 85-96, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29044825

ABSTRACT

INTRODUCTION: Outcome data on treatment of patients with haemophilia A spanning several years of real-world evidence collection are currently very limited. AIM AND METHODS: The global prospective long-term Advate® Haemophilia A Outcome Database (AHEAD) cohort study collects real-world data from patients with severe and moderate haemophilia. We report an interim data read-out after three years of observation. RESULTS: A total of 522 patients were enrolled from 21 countries: 334 completed year 1 follow-up, 238 completed year 2 and 136 completed year 3, with an overall follow-up of 811 patient-years. Median annual bleeding rates (ABR) were 1.7 in the prophylaxis group and 8.9 in the on-demand group at year 1 visit, 1.6 and 13.0, respectively, at year 2 visit and 2.2 and 10.3, respectively, at year 3 visit. Moreover, about 42% of patients on prophylaxis vs 12% of patients on on-demand had zero annual joint bleeding rates (AJBR). Effectiveness of prophylaxis and on-demand treatment was deemed excellent/good in the majority of cases. Octocog alfa (Advate® ) was well tolerated. The inhibitors that developed in nine patients all disappeared spontaneously. Three patients had been previously exposed to FVIII for ≤50 exposure days (EDs), 3 for >50 EDs and 3 showed a borderline positive inhibitory activity (≤0.6 BU/mL). CONCLUSIONS: These data confirm that the goal of zero bleeds is achievable, although not yet achieved in all patients. Understanding reasons behind the lower response to standard prophylaxis regimens in some patients and personalizing prophylactic treatment may further improve outcome in patients with haemophilia A.


Subject(s)
Factor VIII/therapeutic use , Hemophilia A/pathology , Hemorrhage/prevention & control , Adolescent , Adult , Aged , Blood Coagulation Factor Inhibitors/blood , Child , Child, Preschool , Databases, Factual , Factor VIII/adverse effects , Hemophilia A/complications , Hemophilia A/drug therapy , Humans , Infant , Infant, Newborn , Joint Diseases/etiology , Male , Middle Aged , Prospective Studies , Severity of Illness Index , Treatment Outcome , Young Adult
2.
Thromb Res ; 157: 142-146, 2017 Sep.
Article in English | MEDLINE | ID: mdl-28753477

ABSTRACT

INTRODUCTION: Severe blood loss and related haemodilution during cardiac surgery result in a reduced platelet count which may lead to impaired primary haemostasis. Additionally, the reduced haematocrit lowers rheological forces in circulation and may account for lowered platelet adhesiveness and potentially reduced von Willebrand factor (VWF) activity. These mechanisms may lead to postoperative bleeding. Aim of this study was the examination of VWF activity and VWF-mediated platelet adhesion to collagen under conditions of haemodilution. MATERIALS AND METHODS: An in vitro flow chamber was utilized to examine the primary haemostasis under a high arterial shear rate of 1500s-1 at variable VWF concentrations, platelet counts and haematocrit levels. RESULTS: Under a high arterial shear rate, VWF activity is highly dependent on blood viscosity. Both VWF-collagen binding and VWF-mediated platelet adhesion to collagen were significantly increased with increasing haematocrit. Interestingly, we found slight differences in the VWF multimer sizes able to bind collagen under different shear stress conditions. Under conditions of haemodilution, platelet adhesion was strongly dependent on VWF concentration. Increasing VWF concentration improved platelet adhesiveness under low haematocrit conditions (30%) and variable platelet counts (80, 150 and 250×109/L). This effect was nearly abolished at very low platelet count levels of 50×109/L. CONCLUSIONS: VWF improves platelet function under conditions of haemodilution. Therefore, increasing VWF concentration may represent a complementary strategy to administration of platelet concentrates for the management of bleeding in thrombocytopenia.


Subject(s)
Hemodilution/methods , Hemostasis/drug effects , von Willebrand Factor/therapeutic use , Humans , von Willebrand Factor/pharmacology
3.
J Thromb Haemost ; 15(8): 1576-1583, 2017 08.
Article in English | MEDLINE | ID: mdl-28574652

ABSTRACT

Essentials Accurate determination of anticoagulant plasma concentration is important in clinical practice. We studied the accuracy and consistency of anti-Xa assays for rivaroxaban in a multicentre study. In a range between 50 and 200 µg L-1 , anti-Xa activity correlated well with plasma concentrations. The clinical value might be limited by overestimation and intra- and inter-individual variation. SUMMARY: Background Determining the plasma level of direct oral anticoagulants reliably is important in the work-up of complex clinical situations. Objectives To study the accuracy and consistency of anti-Xa assays for rivaroxaban plasma concentration in a prospective, multicenter evaluation study employing different reagents and analytical platforms. Methods Rivaroxaban 20 mg was administered once daily to 20 healthy volunteers and blood samples were taken at peak and trough levels (clinicaltrials.gov NCT01710267). Anti-Xa activity was determined in 10 major laboratories using different reagents and analyzers; corresponding rivaroxaban plasma concentrations were measured by high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS). Findings Overall Pearson's correlation coefficient of anti-Xa levels and HPLC-MS results was 0.99 for Biophen® Heparin (95% CI, 0.99, 0.99), Biophen® DiXaI (95% CI, 0.99, 0.99) and STA® anti-Xa liquid (95% CI, 0.99, 1.00). Correlation was lower in rivaroxaban concentrations below 50 µg L-1 and above 200 µg L-1 . The overall bias of the Bland-Altman difference plot was 14.7 µg L-1 for Biophen Heparin, 17.9 µg L-1 for Biophen DiXal and 19.0 µg L-1 for STA anti-Xa liquid. Agreement between laboratories was high at peak level but limited at trough level. Conclusions Anti-Xa activity correlated well with rivaroxaban plasma concentrations, especially in a range between 50 and 200 µg L-1 . However, anti-Xa assays systematically overestimated rivaroxaban concentration as compared with HPLC-MS, particularly at higher concentrations. This overestimation, coupled with an apparent interindividual variation, might affect the interpretation of results in some situations.


Subject(s)
Blood Coagulation/drug effects , Drug Monitoring/methods , Factor Xa Inhibitors/blood , Factor Xa/metabolism , Rivaroxaban/blood , Administration, Oral , Adolescent , Adult , Aged , Chromatography, High Pressure Liquid , Factor Xa Inhibitors/administration & dosage , Healthy Volunteers , Humans , Laboratory Proficiency Testing , Male , Middle Aged , Observer Variation , Predictive Value of Tests , Prospective Studies , Reproducibility of Results , Rivaroxaban/administration & dosage , Switzerland , Tandem Mass Spectrometry , Young Adult
4.
Haemophilia ; 23(4): e335-e339, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28544263

ABSTRACT

INTRODUCTION: Measuring factor VIII (FVIII) activity can be challenging when it has been modified, such as when FVIII is pegylated to increase its circulating half-life. Use of a product-specific reference standard may help avoid this issue. AIM: Evaluate the impact of using a product-specific reference standard for measuring the FVIII activity of BAX 855 - a pegylated FVIII - in eight of Switzerland's main laboratories. METHODS: Factor VIII-deficient plasma, spiked with five different concentrations of BAX 855, plus a control FVIII sample, was sent to the participating laboratories. They measured FVIII activity by using either with a one-stage (OSA) or the chromogenic assay (CA) against their local or a product-specific reference standard. RESULTS: When using a local reference standard, there was an overestimation of BAX 855 activity compared to the target concentrations, both with the OSA and CA. The use of a product-specific reference standard reduced this effect: mean recovery ranged from 127.7% to 213.5% using the OSA with local reference standards, compared to 110% to 183.8% with a product-specific reference standard, and from 146.3% to 182.4% using the CA with local reference standards compared to 72.7% to 103.7% with a product-specific reference standard. CONCLUSION: In this in vitro study, the type of reference standard had a major impact on the measurement of BAX 855 activity. Evaluation was more accurate and precise when using a product-specific reference standard.


Subject(s)
Biological Assay/standards , Factor VIII/chemistry , Factor VIII/metabolism , Polyethylene Glycols/chemistry , Recombinant Proteins/chemistry , Recombinant Proteins/metabolism , Reference Standards , Switzerland
5.
Oxid Med Cell Longev ; 2016: 1507270, 2016.
Article in English | MEDLINE | ID: mdl-27313824

ABSTRACT

Background. Oxidative stress is a hallmark of CKD and this alteration is strongly implicated in LV hypertrophy and in LV dysfunction. Methods and Patients. We resorted to the strongest genetic biomarker of paraoxonase-1 (PON1) activity, the Q192R variant in the PON1 gene, to unbiasedly assess (Mendelian randomization) the cross-sectional and longitudinal association of this gene-variant with LV mass and function in 206 CKD patients with a 3-year follow-up. Results. The R allele of Q192R polymorphism associated with oxidative stress as assessed by plasma 8-isoPGF2α (P = 0.03) and was dose-dependently related in a direct fashion to LVMI (QQ: 131.4 ± 42.6 g/m(2); RQ: 147.7 ± 51.1 g/m(2); RR: 167.3 ± 41.9 g/m(2); P = 0.001) and in an inverse fashion to systolic function (LV Ejection Fraction) (QQ: 79 ± 12%; RQ: 69 ± 9%; RR: 65 ± 10% P = 0.002). On longitudinal observation, this gene variant associated with the evolution of the same echocardiographic indicators [LVMI: 13.40 g/m(2) per risk allele, P = 0.005; LVEF: -2.96% per risk allele, P = 0.001]. Multivariate analyses did not modify these associations. Conclusion. In CKD patients, the R allele of the Q192R variant in the PON1 gene is dose-dependently related to the severity of LVH and LV dysfunction and associates with the longitudinal evolution of these cardiac alterations. These results are compatible with the hypothesis that oxidative stress is implicated in cardiomyopathy in CKD patients.


Subject(s)
Aryldialkylphosphatase/genetics , Cardiomyopathies/etiology , Oxidative Stress , Renal Insufficiency, Chronic/genetics , Aged , Alleles , Cross-Sectional Studies , Echocardiography , Female , Genotype , Glomerular Filtration Rate , Humans , Longitudinal Studies , Male , Middle Aged , Multivariate Analysis , Polymorphism, Single Nucleotide , Renal Insufficiency, Chronic/complications , Ventricular Function, Left/physiology
6.
Int J Obstet Anesth ; 26: 79-82, 2016 May.
Article in English | MEDLINE | ID: mdl-26775898

ABSTRACT

Heparin-induced thrombocytopenia is a serious adverse event of anticoagulation with a high risk of thromboembolic complications. As a consequence, anticoagulants other than heparins must be administered. These may be unavailable, contraindicated during pregnancy, off-label, impractical due to short half-lives and, most importantly, may be unfamiliar to many anesthesiologists. Impaired coagulation bears the risk of adverse events following neuraxial procedures and of peripartum hemorrhage. We describe the case of heparin-induced thrombocytopenia in a 29-year-old pregnant woman at 27weeks of gestation with severe valvular heart disease.


Subject(s)
Heparin/adverse effects , Pregnancy Complications, Hematologic/chemically induced , Thrombocytopenia/chemically induced , Adult , Female , Humans , Pregnancy
7.
Am J Transplant ; 15(10): 2588-601, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25966640

ABSTRACT

T cell depletion with antithymocyte globulins (ATG) can be complicated by thrombopenia and hypercoagulability. The underlying mechanism is still unclear. We found that binding of ATG to platelets caused platelet aggregation, α-granule release, membrane phosphatidylserine exposure and the rapid release of procoagulant platelet microvesicles (MV). Platelet activation and MV release were complement-dependent and required membrane insertion of C5b-8 but not stable lytic pore formation by C5b-9. ATG also activated platelets via binding to the low-affinity Fc gamma receptor FcγRII. However, only complement inhibition but not blockade of FcγRII prevented MV release and subsequent thrombin activation in plasma. In 19 hematopoietic stem cell and kidney transplant patients, ATG treatment resulted in thrombopenia and increased plasma levels of d-dimer and thrombin-antithrombin complexes. Flow cytometric analysis of complement fragments on platelet MV in patient plasma confirmed dose-dependent complement activation by ATG. However, the rapid rise in MV numbers observed in vitro was not seen during ATG treatment. In vitro experiments suggested that this was due to adherence of C3b-tagged MV to red blood cells via complement receptor CR1. These data suggest a clinically relevant link between complement activation and thrombin generation and offer a potential mechanism underlying ATG-induced hypercoagulability.


Subject(s)
Antilymphocyte Serum/adverse effects , Hematopoietic Stem Cell Transplantation , Immunosuppressive Agents/adverse effects , Kidney Transplantation , Platelet Activation/drug effects , Thrombophilia/chemically induced , Antilymphocyte Serum/therapeutic use , Biomarkers/blood , Cell-Derived Microparticles/drug effects , Complement Activation/drug effects , Graft Rejection/immunology , Graft Rejection/prevention & control , Graft vs Host Disease/immunology , Graft vs Host Disease/prevention & control , Humans , Immunosuppressive Agents/therapeutic use , Platelet Activation/immunology , Thrombin/metabolism , Thrombocytopenia/blood , Thrombocytopenia/chemically induced , Thrombocytopenia/diagnosis , Thrombophilia/blood , Thrombophilia/diagnosis
8.
Bioinspir Biomim ; 10(3): 035005, 2015 May 13.
Article in English | MEDLINE | ID: mdl-25970151

ABSTRACT

The outstanding locomotor and manipulation characteristics of the octopus have recently inspired the development, by our group, of multi-functional robotic swimmers, featuring both manipulation and locomotion capabilities, which could be of significant engineering interest in underwater applications. During its little-studied arm-swimming behavior, as opposed to the better known jetting via the siphon, the animal appears to generate considerable propulsive thrust and rapid acceleration, predominantly employing movements of its arms. In this work, we capture the fundamental characteristics of the corresponding complex pattern of arm motion by a sculling profile, involving a fast power stroke and a slow recovery stroke. We investigate the propulsive capabilities of a multi-arm robotic system under various swimming gaits, namely patterns of arm coordination, which achieve the generation of forward, as well as backward, propulsion and turning. A lumped-element model of the robotic swimmer, which considers arm compliance and the interaction with the aquatic environment, was used to study the characteristics of these gaits, the effect of various kinematic parameters on propulsion, and the generation of complex trajectories. This investigation focuses on relatively high-stiffness arms. Experiments employing a compliant-body robotic prototype swimmer with eight compliant arms, all made of polyurethane, inside a water tank, successfully demonstrated this novel mode of underwater propulsion. Speeds of up to 0.26 body lengths per second (approximately 100 mm s(-1)), and propulsive forces of up to 3.5 N were achieved, with a non-dimensional cost of transport of 1.42 with all eight arms and of 0.9 with only two active arms. The experiments confirmed the computational results and verified the multi-arm maneuverability and simultaneous object grasping capability of such systems.


Subject(s)
Biomimetics/instrumentation , Extremities/physiology , Octopodiformes/physiology , Robotics/instrumentation , Ships/instrumentation , Swimming/physiology , Animals , Equipment Design , Equipment Failure Analysis , Rheology/instrumentation
9.
Comput Methods Biomech Biomed Engin ; 18(12): 1321-39, 2015.
Article in English | MEDLINE | ID: mdl-24730546

ABSTRACT

The fluid dynamics of cephalopods has so far received little attention in the literature, due to their complexity in structure and locomotion. The flow around octopuses, in particular, can be complicated due to their agile and dexterous arms, which frequently display some of the most diverse mechanisms of motion. The study of this flow amounts to a specific instance of the hydrodynamics problem for rough tapered cylinder geometries. The outstanding manipulative and locomotor skills of octopuses could inspire the development of advanced robotic arms, able to operate in fluid environments. Our primary aim was to study the hydrodynamic characteristics of such bio-inspired robotic models and to derive the hydrodynamic force coefficients as a concise description of the vortical flow effects. Utilizing computational fluid dynamic methods, the coefficients were computed on realistic morphologies of octopus-like arm models undergoing prescribed solid-body movements; such motions occur in nature for short durations in time, e.g. during reaching movements and exploratory behaviors. Numerical simulations were performed on translating, impulsively rotating, and maneuvering arms, around which the flow field structures were investigated. The results reveal in detail the generation of complex vortical flow structures around the moving arms. Hydrodynamic forces acting on a translating arm depend on the angle of incidence; forces generated during impulsive rotations of the arms are independent of their exact morphology and the angle of rotation; periodic motions based on a slow recovery and a fast power stroke are able to produce considerable propulsive thrust while harmonic motions are not. Parts of these results have been employed in bio-inspired models of underwater robotic mechanisms. This investigation may further assist elucidating the hydrodynamics underlying aspects of octopus locomotion and exploratory behaviors.


Subject(s)
Extremities/physiology , Hydrodynamics , Models, Theoretical , Octopodiformes/physiology , Swimming/physiology , Animals , Biomechanical Phenomena , Robotics/methods
11.
Article in English | MEDLINE | ID: mdl-23025686

ABSTRACT

An implicit nonlinear finite element model for simulating biological muscle mechanics is developed. The numerical method is suitable for dynamic simulations of three-dimensional, nonlinear, nearly incompressible, hyperelastic materials that undergo large deformations. These features characterise biological muscles, which consist of fibres and connective tissues. It can be assumed that the stress distribution inside the muscles is the superposition of stresses along the fibres and the connective tissues. The mechanical behaviour of the surrounding tissues is determined by adopting a Mooney-Rivlin constitutive model, while the mechanical description of fibres is considered to be the sum of active and passive stresses. Due to the nonlinear nature of the problem, evaluation of the Jacobian matrix is carried out in order to subsequently utilise the standard Newton-Raphson iterative procedure and to carry out time integration with an implicit scheme. The proposed methodology is implemented into our in-house, open source, finite element software, which is validated by comparing numerical results with experimental measurements and other numerical results. Finally, the numerical procedure is utilised to simulate primitive octopus arm manoeuvres, such as bending and reaching.


Subject(s)
Finite Element Analysis , Models, Biological , Muscle, Skeletal/physiology , Animals , Biomechanical Phenomena , Connective Tissue/physiology , Decapodiformes , Muscle, Skeletal/anatomy & histology , Nonlinear Dynamics , Octopodiformes , Ranidae
12.
Praxis (Bern 1994) ; 101(7): 465-71, 2012 Mar 28.
Article in German | MEDLINE | ID: mdl-22454308

ABSTRACT

Heritable thrombophilia as a concept in hemostasis has been continuously discovered parallel to the knowledge on physiology of bleeding disorders. Since the 1980s it has become increasingly popular to search for thrombophilia in patients with thromboembolism and their relatives. Although initially no direct evidence existed for any advantage for the patients, successive clinical studies have helped to understand the risk of thrombosis and to stratify the patients in relation to the thrombophilic defect. In the meantime national and international guidelines have been published, suggesting which candidates should be examined and what tests should be performed. In the present paper we summarise and explain the rationale of these guidelines from the european point of view.


Subject(s)
Mass Screening , Thrombophilia/diagnosis , Adult , Aged , Blood Coagulation Tests , Genetic Predisposition to Disease , Humans , Middle Aged , Practice Guidelines as Topic , Recurrence , Risk Factors , Switzerland , Thromboembolism/diagnosis , Thromboembolism/genetics , Thrombophilia/genetics
13.
Br J Anaesth ; 108(5): 754-62, 2012 May.
Article in English | MEDLINE | ID: mdl-22311365

ABSTRACT

BACKGROUND: Severe aortic stenosis is associated with loss of the largest von Willebrand factor (vWF) multimers, which could affect primary haemostasis. We hypothesized that the altered multimer structure with the loss of the largest multimers increases postoperative bleeding in patients undergoing aortic valve replacement. METHODS: We prospectively included 60 subjects with severe aortic stenosis. Before and after aortic valve replacement, vWF antigen, activity, and multimer structure were determined and platelet function was measured by impedance aggregometry. Blood loss from mediastinal drainage and the use of blood and haemostatic products were evaluated perioperatively. RESULTS: Before operation, the altered multimer structure was present in 48 subjects (80%). Baseline characteristics and laboratory data were similar in all subjects. The median blood loss after 6 h was 250 (105-400) and 145 (85-240) ml in the groups with the altered and normal multimer structures, respectively (P=0.182). After 24 h, the cumulative loss was 495 (270-650) and 375 (310-600) ml in the groups with the altered and normal multimer structures, respectively (P=0.713). Multivariable analysis revealed no significant influence of multimer structure and platelet function on bleeding volumes after 6 and 24 h. After 24 h, there was no obvious difference in vWF antigen, activity, and multimer structure in subjects with and without the altered multimer structure before operation or in subjects with and without perioperative plasma transfusion. CONCLUSIONS: The altered vWF multimer structure before operation was not associated with increased bleeding after aortic valve replacement. Our findings might be explained by perioperative release of vWF and rapid recovery of the largest vWF multimers.


Subject(s)
Aortic Valve Stenosis/surgery , Heart Valve Prosthesis Implantation/adverse effects , Postoperative Hemorrhage/blood , von Willebrand Factor/metabolism , Aged , Aged, 80 and over , Aortic Valve Stenosis/blood , Biomarkers/blood , Blood Specimen Collection/methods , Blood Transfusion , Female , Follow-Up Studies , Humans , Male , Molecular Weight , Platelet Aggregation/physiology , Postoperative Hemorrhage/etiology , Prospective Studies , Protein Multimerization
14.
Hamostaseologie ; 32(1): 63-6, 2012.
Article in English | MEDLINE | ID: mdl-22083512

ABSTRACT

Allogeneic and autologous hematopoietic stem cell transplantations are important therapeutic options for patients with hematologic disorders. Hemostatic complications are frequent after hematopoietic stem cell transplantation with a considerable morbidity and mortality. The incidence of bleedings and thrombosis is highest in the first few weeks after transplantation, but may also occur later. However, beyond the first year of transplantation only limited data are available. In long-term survivors the risk for premature atherosclerosis increases over time after allogeneic hematopoietic stem cell transplantation and it is higher than in the age-adjusted general population and in recipients of autologous transplantation.


Subject(s)
Acute-Phase Reaction/epidemiology , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Hemorrhage/epidemiology , Hemostasis , Postoperative Complications/epidemiology , Thrombosis/epidemiology , Comorbidity , Germany/epidemiology , Humans , Prevalence , Risk Assessment , Risk Factors
15.
Thromb Res ; 129(4): 492-8, 2012 Apr.
Article in English | MEDLINE | ID: mdl-21840043

ABSTRACT

INTRODUCTION: Rivaroxaban (RXA) is licensed for prophylaxis of venous thromboembolism after major orthopaedic surgery of the lower limbs. Currently, no test to quantify RXA in plasma has been validated in an inter-laboratory setting. Our study had three aims: to assess i) the feasibility of RXA quantification with a commercial anti-FXa assay, ii) its accuracy and precision in an inter-laboratory setting, and iii) the influence of 10mg of RXA on routine coagulation tests. METHODS: The same chromogenic anti-FXa assay (Hyphen BioMed) was used in all participating laboratories. RXA calibrators and sets of blinded probes (aim ii.) were prepared in vitro by spiking normal plasma. The precise RXA content was assessed by high-pressure liquid chromatography-tandem mass spectrometry. For ex-vivo studies (aim iii), plasma samples from 20 healthy volunteers taken before and 2 - 3hours after ingestion of 10mg of RXA were analyzed by participating laboratories. RESULTS: RXA can be assayed chromogenically. Among the participating laboratories, the mean accuracy and the mean coefficient of variation for precision of RXA quantification were 7.0% and 8.8%, respectively. Mean RXA concentration was 114±43µg/L .RXA significantly altered prothrombin time, activated partial thromboplastin time, factor analysis for intrinsic and extrinsic factors. Determinations of thrombin time, fibrinogen, FXIII and D-Dimer levels were not affected. CONCLUSIONS: RXA plasma levels can be quantified accurately and precisely by a chromogenic anti-FXa assay on different coagulometers in different laboratories. Ingestion of 10mg RXA results in significant alterations of both PT- and aPTT-based coagulation assays.


Subject(s)
Artifacts , Blood Coagulation Tests/methods , Drug Monitoring/methods , Factor Xa Inhibitors , Morpholines/blood , Thiophenes/blood , Adult , Anticoagulants/blood , Humans , Male , Reproducibility of Results , Rivaroxaban , Sensitivity and Specificity , Switzerland
16.
Bone Marrow Transplant ; 46(3): 344-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20548339

ABSTRACT

BU-CY is the established non-TBI-based myeloablative conditioning regimen for allogeneic hematopoietic SCT. However, liver toxicity and hepatic veno-occlusive disease (VOD) are frequent life-threatening complications. Pharmacological considerations suggest that BU can trigger toxicity of subsequent CY. Recent animal data confirmed this hypothesis. Less liver toxicity and better outcomes were observed when mice were treated with the reversed order of CY and BU. We analyzed in this study liver toxicity and outcome in patients receiving BU-CY (16 patients) or CY-BU (59 patients). Liver function differed significantly with higher levels of liver function tests between day +10 and +30, and a higher cumulative incidence of VOD in the BU-CY cohort (2/16 (12.5%) vs 0/59 (0%), P=0.006). TRM was significantly higher in patients receiving BU-CY (cumulative incidence BU-CY 45%, CY-BU 17%, P=0.02), without yet translating into a significant survival difference (incidence for survival: BU-CY 38%, CY-BU 63%; hazard ratio 1.19 for BU-CY, 95% confidence interval 0.29-4.82, P=0.80). Rates of engraftment and relapse were not different. These data support the concepts derived from animal models in favor of CY-BU compared with traditional BU-CY and form the basis for prospective controlled comparisons.


Subject(s)
Busulfan/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Cyclophosphamide/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatic Veno-Occlusive Disease/chemically induced , Liver/drug effects , Transplantation Conditioning/adverse effects , Adolescent , Adult , Aged , Busulfan/administration & dosage , Chemical and Drug Induced Liver Injury/immunology , Chemical and Drug Induced Liver Injury/pathology , Cohort Studies , Cyclophosphamide/administration & dosage , Drug Administration Schedule , Female , Graft vs Host Disease/immunology , Graft vs Host Disease/prevention & control , Hepatic Veno-Occlusive Disease/immunology , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Liver/pathology , Male , Middle Aged , Retrospective Studies , Transplantation Conditioning/methods , Treatment Outcome , Young Adult
17.
Internist (Berl) ; 52(1): 89-98, 2011 Jan.
Article in German | MEDLINE | ID: mdl-21088954

ABSTRACT

Anesthesiologists and surgeons are increasingly faced with patients who are under long-term medication. Some of these drugs can interact with anaesthetics or anaesthesia and/or surgical interventions. As a result, patients may experience complications such as bleeding, ischemia, infection or severe circulatory reactions. On the other hand, perioperative discontinuation of medication is often more dangerous. The proportion of outpatient operations has increased dramatically in recent years and will probably continue to increase. Since the implementation of DRGs (pending in Switzerland, introduced in Germany for some time), the patient enters the hospital the day before operation. This means that the referring physician as well as anesthesiologists and surgeons at an early stage must deal with issues of perioperative pharmacotherapy. This review article is about the management of the major drug classes during the perioperative period. In addition to cardiac and centrally acting drugs and drugs that act on hemostasis and the endocrine system, special cases such as immunosuppressants and herbal remedies are mentioned.


Subject(s)
Drug Therapy/methods , Drug-Related Side Effects and Adverse Reactions/prevention & control , Perioperative Care/methods , Premedication/adverse effects , Premedication/methods , Humans
18.
Anaesthesist ; 60(5): 451-6, 2011 May.
Article in German | MEDLINE | ID: mdl-21184040

ABSTRACT

Thrombotic microangiopathies are characterized by platelet activation, endothelial damage, hemolysis and microvascular occlusion. This group of diseases is primary represented by thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome (HUS). Patients present with microangiopathic hemolytic anemia and thrombocytopenia as well as occlusion-related organ ischemia to a variable degree. A deficiency of the metalloprotease ADAMTS-13 is a major risk for acute disease manifestation as this is a regulator of unusually large von Willebrand factor (vWF) multimers, which are extremely adhesive and secreted by endothelial cells. In classical TTP an ADAMTS-13 activity below 5% is specific, whereas in other forms of thrombotic microangiopathies activity of ADAMTS-13 ranges from very low to normal. Symptoms of different forms of thrombotic microangiopathy are frequently overlapping and a clear classification according to clinical criteria is often difficult. Due to a high mortality, particularly of TTP, immediate diagnosis and therapy are essential. In this article two cases of thombotic microangiopathy after cardiac surgery are reported. After exclusion of TTP and HUS as well as other etiologies of thrombotic microangiopathy a relationship between the use of extracorporeal circulation and the pathogenesis of thrombotic microangiopathy is assumed.


Subject(s)
Extracorporeal Circulation/adverse effects , Peripheral Vascular Diseases/diagnosis , Peripheral Vascular Diseases/etiology , Thrombosis/etiology , ADAM Proteins/genetics , ADAMTS13 Protein , Aged, 80 and over , Aortic Diseases/complications , Aortic Diseases/surgery , Aspirin/therapeutic use , Coma/etiology , Critical Care , Diagnosis, Differential , Female , Hemolytic-Uremic Syndrome/etiology , Hemolytic-Uremic Syndrome/therapy , Humans , Male , Middle Aged , Mitral Valve Insufficiency/complications , Mitral Valve Insufficiency/surgery , Peripheral Vascular Diseases/genetics , Platelet Aggregation Inhibitors/therapeutic use , Postoperative Complications/genetics , Postoperative Complications/therapy , Purpura, Thrombocytopenic/etiology , Purpura, Thrombocytopenic/therapy , Risk Factors , von Willebrand Factor/genetics
20.
Int J Lab Hematol ; 32(3): 329-35, 2010 Jun.
Article in English | MEDLINE | ID: mdl-19706066

ABSTRACT

The diagnosis of sideroblastic anemia is based on bone marrow aspiration, and the detection of ring sideroblasts (RS) in iron staining. The finding of laboratory parameters to approach this diagnosis still remains a great challenge. In this study, we analyzed the value of a specific erythrogram pattern from peripheral blood, produced by the ADVIA120 cell counter, to predict sideroblastic changes in the bone marrow. In a two step-design study, we first showed that 32/38 consecutive patients reporting > or =15% RS had such a pattern in the erythrogram. In the second step, we prospectively identified over a period of 32 months 21 patients with this typical erythrogram; 20/21 had > or =15% RS in the bone marrow. Hence, by this validation, we confirm that the erythrogram is highly predictive of RS in the bone marrow. The interpretation of the erythrogram should become daily practice in hematology to improve the efficacy to detect sideroblastic changes.


Subject(s)
Anemia, Sideroblastic , Bone Marrow/physiopathology , Erythroblasts/cytology , Adult , Aged , Aged, 80 and over , Anemia, Sideroblastic/blood , Anemia, Sideroblastic/diagnosis , Erythrocyte Indices , Female , Humans , Longitudinal Studies , Male , Middle Aged , Predictive Value of Tests , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL
...